HIGHLIGHTS
- who: Dr Daniel I Swerdlow PhD et al. from the University ofCambridge, UK have published the Article: HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, in the Journal: (JOURNAL) of September/24,/2014
- what: The authors aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) the intended drug target. One small trial34 that was ineligible for this study reported 2 months of atorvastatin treatment led to higher glycated haemoglobin (HbA1c) and insulin concentrations and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.